Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension. J of Skin [Internet]. 2022 Nov. 16 [cited 2026 May 1];6(6):s68. Available from: https://skin.dermsquared.com/skin/article/view/1824